Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Efruxifermin (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms BALANCED
- Sponsors Akero Therapeutics
- 24 Aug 2022 Results published in an Akero Therapeutics Media Release.
- 24 Aug 2022 According to an Akero Therapeutics media release, results from Cohort C have been published in JHEP Reports.
- 27 Jun 2022 Post hoc analysis(n=58) published in the Akero Therapeutics Media Release.